Pharma BD Deal Intelligence

Johnson & Johnson / Ollin Biosciences

2026 · Acquisition/Merger · $3.3B · Pending

Johnson & Johnson agreed to acquire clinical-stage Ollin Biosciences for $2.2 billion in cash upfront, with up to approximately $1.125 billion in additional regulatory and commercial milestone payments. The acquisition brings OLN324, a Phase 3-stage investigational bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), two pathways implicated in retinal vascular disease. OLN324 uses a minibody format with enhanced Ang2 potency, which J&J positions as offering improved retinal fluid control, more durable responses and longer intervals between intravitreal injections. Target indications are wet age-related macular degeneration and diabetic macular edema. Separately, Blackstone Life Sciences will pay Johnson & Johnson a total of $750 million over multiple years to fully fund Phase 3 development of OLN324. The transaction is expected to close before the end of 2026.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →